Table 1. Characteristics of the human cell lines used for sensitivity testing and validation of the HRM analysis technique for KRAS mutation detection.
| Cell line | Origin (human) | Mutation | Reference |
|---|---|---|---|
| A549 | Lung carcinoma | KRAS exon 2: G12S homozygous | Krypuy et al, 2006 |
| CAL27 | Head and neck carcinoma | ||
| ECV304 | Bladder carcinoma | ||
| SQD9 | Head and neck squamous carcinoma | ||
| NCI-H292 | Lung carcinoma | ||
| HCT116 | Colon carcinoma | KRAS exon 2: G13D heterozygous | Krypuy et al, 2006; Simi et al, 2008 |
| MDA-MB231 | Breast carcinoma | KRAS exon 2: G13D heterozygous | Cosmic data set, Welcome Trust Sanger Institute, 2009: http://www.sanger.ac.uk/perl/genetics/CPG/core_line_viewer?action=sample&id=909960 |
Abbreviation: HRM=high-resolution melting.